E-Mail
New York, NY (April 10, 2021) - A personalized cancer vaccine developed with the help of a Mount Sinai computational platform raised no safety concerns and showed potential benefit in patients with different cancers, including lung and bladder, that have a high risk of recurrence, according to results from an investigator-initiated phase I clinical trial presented during the virtual American Association for Cancer Research (AACR) Annual Meeting 2021, held April 10-15. While immunotherapy has revolutionized the treatment of cancer, the vast majority of patients do not experience a significant clinical response with such treatments, said study author Thomas Marron, MD, PhD, Assistant Director for Early Phase and Immunotherapy Trials at The Tisch Cancer Institute and Assistant Professor of Medicine (Hematology and Medical Oncology) at the Icahn School of Medicine at Mount Sinai. Cancer vaccines, which typically combine tumor-specific targets that the immune system can lear
NuCana plc
NuCana Announces Five Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021
NuCana Announces Five Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021
NUC-3373 Shows Encouraging Efficacy Signals and a Favorable Safety Profile in Patients with Advanced Colorectal Cancer
NUC-3373 Promotes Natural Killer Cell Activation by Colorectal Cancer Cells
NUC-7738 Demonstrates Anti-Cancer Activity, Prolonged Stable Disease and a Favorable Tolerability Profile in Patients with Advanced Solid Tumors
NUC-7738 Generates High and Prolonged Intracellular Levels of the Active Anti-Cancer Metabolite 3’-dATP
Acelarin Induces Persistent DNA Damage in Biliary Tract Cancer Cells
EDINBURGH, United Kingdom, April 10, 2021 (GLOBE NEWSWIRE) NuCana plc (NASDAQ: NCNA) announced the presentation of five posters at the American Association for Cancer Research (AACR) Annual Meeting 2021 being held virtually
Sumitomo Dainippon Pharma Oncology Presents New Data from Investigational Pipeline of Novel Cancer Therapeutics at AACR Virtual Annual Meeting I 2021
News provided by
Share this article
Share this article
CAMBRIDGE, Mass., April 10, 2021 /PRNewswire/ Sumitomo Dainippon Pharma Oncology, Inc., a clinical-stage company focused on research and development for novel cancer therapeutics, today presented new findings on a range of investigational agents from the company s pipeline at the American Association for Cancer Research (AACR) Virtual Annual Meeting I, taking place April 10-15, 2021.
The data presented at the meeting include preclinical and Phase 1 clinical data evaluating the potential anti-cancer activity of the PKM2 activator TP-1454, PIM inhibitor TP-3654, TNK1 inhibitor TP-5809 and CDK9 inhibitor alvocidib. Additionally, Sumitomo Dainippon Pharma Co., Ltd., the parent company of Sumitomo Dainippon Pharma Oncology (SDP Oncology), presented findings from preclinical stud
Share this article
Share this article
SAN DIEGO, April 10, 2021 /PRNewswire/ Mirati Therapeutics, Inc. (NASDAQ: MRTX), a late-stage targeted oncology company, today announced initial preclinical results evaluating its investigational synthetic lethal PRMT5 inhibitor in methylthioadenosine phosphorylase (
MTAP)-deleted cancer models. Mirati s internally discovered PRMT5 compound is the first to specifically target the PRMT5/methylthioadenosine (MTA) complex. This approach is designed to leverage elevated levels of MTA in cancers exhibiting an
MTAP deletion and to selectively kill cancer cells harboring this genetic alteration. The results were presented today during a late-breaking minisymposium at the 2021 American Association for Cancer Research (AACR) Virtual Annual Meeting [Abstract # LB003].
email article
A novel bispecific protein significantly improved overall survival (OS) in metastatic uveal melanoma as compared with investigator s choice of treatment, including checkpoint inhibitors, a randomized trial showed.
Patients treated with tebentafusp had a median OS of 21.7 months versus 16.0 months for the control group. The benefit was consistent across all prespecified subgroups.
Grade 3/4 treatment-related adverse events (TRAEs) occurred infrequently, including a 1% incidence of severe cytokine release syndrome (CRS), reported Jessica C. Hassel, MD, of University Hospital Heidelberg in Germany, at the American Association for Cancer Research (AACR) virtual meeting. Tebentafusp showed a highly significant and clinically meaningful improvement in overall survival as first-line treatment of metastatic uveal melanoma, she said. It is the first investigational therapy in a phase III trial to improve overall survival in metastatic uveal melanoma, and this overal